当前位置:
X-MOL 学术
›
Cancer Discov.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Crizotinib Has Antitumor Activity in ALK-Positive ALCL and IMT
Cancer Discovery ( IF 28.2 ) Pub Date : 2017-08-18 , DOI: 10.1158/2159-8290.cd-rw2017-154 American Association for Cancer Research
中文翻译:
克唑替尼在ALK阳性ALCL和IMT中具有抗肿瘤活性
更新日期:2017-09-21
Cancer Discovery ( IF 28.2 ) Pub Date : 2017-08-18 , DOI: 10.1158/2159-8290.cd-rw2017-154 American Association for Cancer Research
Crizotinib has an overall response rate of 90% in ALCL and 86% in IMT at the recommended phase II dose.
中文翻译:
克唑替尼在ALK阳性ALCL和IMT中具有抗肿瘤活性
在推荐的II期剂量下,克唑替尼在ALCL中的总体缓解率为90%,在IMT中的总体缓解率为86%。